BCL2 and B-cell chronic lymphocytic leukemia: Venetoclax (ABT‐199) is a potent and selective inhibitor of Bcl‐2, approved for treating chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) in patients with specific genetic profiles indicating Bcl‐2 dependence.141, 158